Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares

Rhea-AI Filing Summary

Aktis Oncology, Inc. executive Shulamit Ron-Bigger, Chief Operating Officer, reported an exercise-and-sale transaction in company equity. On July 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $3.66 per share and on the same date sold 50,000 shares of common stock in multiple open-market transactions at weighted average prices around the high-$20s per share. After these transactions, she continued to hold 217,888 stock options expiring in 2032.

Insights

Equity compensation analyst

COO exercised 50,000 options and sold the resulting shares, retaining a sizable option position.

Chief Operating Officer Shulamit Ron-Bigger exercised options for 50,000 shares at an exercise price of $3.66 per share and sold 50,000 common shares in open-market transactions on July 8, 2026. This is a classic exercise-and-sell pattern, turning an in-the-money option grant into cash while originating from equity compensation rather than open-market buying.

Following the derivative transaction, she held 217,888 stock options expiring on October 30, 2032, indicating ongoing equity exposure to Aktis Oncology. Weighted-average sale prices were reported for each sale tranche, with underlying trade prices spanning ranges such as $26.52 to $28.76, but the filing does not indicate any Rule 10b5-1 trading plan. As a result, the activity looks like discretionary liquidity management while leaving a substantial residual option stake.

Insider Trade Summary

Net Seller: 50,000 shares ($1,387,558)

Net Sell 5 txns

Insider Ron-Bigger Shulamit

Role Chief Operating Officer

Sold 50,000 shs ($1.39M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	50,000	$0.00	--
Exercise	Common Stock	50,000	$3.66	$183K
Sale	Common Stock	15,800	$27.1317	$429K
Sale	Common Stock	30,000	$27.9379	$838K
Sale	Common Stock	4,200	$28.7476	$121K

Holdings After Transaction: Stock Option (Right to Buy) — 217,888 shares (Direct); Common Stock — 50,000 shares (Direct)

Footnotes (1)

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5200 to $28.4700, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.7300 to $28.7600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the original number of shares subject to the option vested on September 19, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Key Figures

Shares sold: 50,000 shares of Common Stock Option exercise price: $3.66 per share Sale price tranche 1: $27.1317 per share +4 more

7 metrics

Shares sold 50,000 shares of Common Stock Total open-market sale volume reported on July 8, 2026

Option exercise price $3.66 per share Exercise price for 50,000 stock options converted into common stock

Sale price tranche 1 $27.1317 per share Weighted average price for a 15,800-share open-market sale tranche

Sale price tranche 2 $27.9379 per share Weighted average price for a 30,000-share open-market sale tranche

Sale price tranche 3 $28.7476 per share Weighted average price for a 4,200-share open-market sale tranche

Options remaining 217,888 stock options Stock Option (Right to Buy) position following the reported exercise

Option expiration October 30, 2032 Expiration date of the Stock Option (Right to Buy) award

Key Terms

open-market sale, Stock Option (Right to Buy), weighted average price, vesting

4 terms

open-market sale financial

"transaction_action is described as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy) with underlying shares"

weighted average price financial

"The price reported is a weighted average price for multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vesting financial

"25% of the original number of shares subject to the option vested on September 19, 2023"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 06:11 AM Accepted by SEC EDGAR 07/10/2026 - 06:11 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ron-Bigger Shulamit

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		M		50,000	A	$3.66	50,000	D
Common Stock	07/08/2026		S		15,800	D	$27.1317(1)	34,200	D
Common Stock	07/08/2026		S		30,000	D	$27.9379(2)	4,200	D
Common Stock	07/08/2026		S		4,200	D	$28.7476(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.66	07/08/2026		M			50,000	(4)	10/30/2032	Common Stock	50,000	$0	217,888	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5200 to $28.4700, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.7300 to $28.7600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. 25% of the original number of shares subject to the option vested on September 19, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

	/s/ Kyle D. Kuvalanka, as Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)